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ABS TRACT:
Paraoxonase (PON1) L55M and Q192R polymorphisms in major depressive disorder and bipolar 
disorder
Objective: Oxidative and nitrosative stress pathways, along with immune-inflammatory response, might play an 
important role in the pathogenic mechanisms underlying major depressive disorder and bipolar disorder. The aim of the 
present study is to investigate paraoxonase 1 polymorphisms and its correlations with disease parameters in patients 
with major depressive disorder and bipolar disorder. 
Methods: PON1 L55M and Q192R single nucleotide polymorphisms were analyzed in a group consisted of 100 patients 
with major depressive disorder, and 100 patients with bipolar disorder and 96 healthy controls. Polymorphisms were 
analyzed by using polymerase chain reaction. 
Results: There were no statistically significant differences between groups for the existence of PON1 genotypes. 
Additionally, there was no association between the PON1 genotypes and disease variables in both depressed and bipolar 
patients.
Conclusions: Evaluating the different stages of patients with mood disorders and examining the connection between 
PON1 polymorphisms and treatment outcomes will help us to clarify the relationship between PON1 and mood disorders.
Keywords: paraoxonase (PON1), polymorphism, depression, bipolar disorder, association study 
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INTRODUCTION 
Mood disorders are thought to be caused by a combination 
of environmental, psychological, biological, and genetic 
factors. It was shown that oxidative/nitrosative stresses 
pathways, along with immune-inflammatory response, 
might play an important role in the pathogenic mechanisms 
underlying major depressive disorder and bipolar disorder 
(1). Reactive oxygen species affect both the immune-
inflammatory pathways and the expression of key 
neurotransmitters  which are  involved in  the 
pathophysiology of depression (2). Studies demonstrated 
discrepancies in antioxidant enzyme levels in different 
stages of bipolar disorder (3,4). Additionally, adding 
antioxidant agents to treatment of patients with bipolar 
disorder caused a substantial decrease in depressive 
symptoms and increase in clinical functioning or quality of 
life measures (5).
 Paraoxonase is a calcium-dependent esterase that 
catalyzes the hydrolysis of neurotoxins such as 
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organophosphates and aromatic carboxylic acids (6). The 
paraoxonase (PON) gene family has three members, PON1, 
PON2, and PON3. PON1 is an important enzyme playing a 
role in inactivating the organophosphates in the brain. 
Human paraoxonase 1 (PON1) is a high-density lipoprotein 
(HDL)-associated serum enzyme that exhibits a broad 
substrate specificity (7). The PON1 enzyme has both 
paraoxonase and arylesterase activity and shows anti-
inflammatory and antioxidative properties (8). The PON1 
gene contains two common polymorphisms found in the 
PON1 coding region, leading to a glutamine (Q) → arginine 
(R) substitution at position 192 (Q192R; rs 662) and to a 
leucine (L) → methionine (M) substitution at position 55 
(L55M; rs 854560) ( 9). The L55M polymorphism affects the 
enzyme concentration and the Q192R polymorphism is 
responsible for the hydrolytic activity of the enzyme (10,11). 
Studies concerning the relationship between PON1 
polymorphisms and mood disorders exhibited inconsistent 
results. It was reported that PON1 Q192R polymorphism 
may be associated with symptoms of depression in older 
women (12). Another study demonstrated that PON1 
Q192R-smoking interaction predicted the odds of 
depression (13). Contrarily, no associations were detected 
between mood disorders and any of the Q192R genotypes 
(14). In a genome-wide association study, the authors 
reported no associations between major depressive 
disorder and the Q192R polymorphism or any other 
polymorphism in the PON1 gene (15) Also, no significant 
associat ions were found between PON1Q192R 
polymorphism and depression in population-based studies 
(16). While some studies found no differences in terms of 
PON1 activity between patients with depression and 
controls (17,18); others demonstrated a diminished PON1 
activity (13,19-20). Furthermore, it was indicated that 
antidepressant treatment increased the decreased 
paraoxonase/arylesterase levels (20).
 It was demonstrated that carrying homozygote or 
heterozygote mutated alleles of L55M and Q192R might 
cause susceptibility to bipolar I disorder (9). The odds of 
bipolar disorder were increased by the QQ genotype of 
Q192R in cigarette smokers (13). In a genome-wide 
association study, no associations between bipolar disorder 
and the Q192R polymorphism or any other polymorphism 
in the PON1 gene was found. Two studies investigated 
PON1 activity in bipolar patients. The first study reported 
normal PON1 activity (13) but the other showed decreased 
PON1 activity in bipolar patients (21). In a study consisting 
of both depressed and bipolar patients; decreased PON1 
activity was found to be associated with comorbid mood 
disorders and tobacco use disorder (14). In terms of 
polymorphisms, there were no significant associations 
between the patient groups and any of the three PON1 
Q192R genotypes in the same study.
 There are inconsistent results with regard to the 
relationship between PON1 polymorphism and mood 
disorders. Besides, the allele frequencies of PON1 varied 
substantially among races. The aim of the present study is 
to investigate the two common paraoxonase 1 
polymorphisms and its correlations with disease 
parameters in patients with major depressive disorder and 
bipolar disorder in a sample from Turkey. 
METHODS
This study used the serum specimens of a former study 
entitled: “Investigation of Dopamine-β-hydroxylase 
Polymorphism in Patients with Major Depression, Bipolar 
Disorder, and Schizophrenia”. The study group consisted of 
100 patients with major depression (83 females and 17 
males), and 100 patients with bipolar affective disorder (49 
females and 51 males) and 96 healthy controls (48 females 
and 48 males). All depressed and bipolar patients were 
followed up at a university hospital outpatient psychiatry 
clinic. Diagnoses of major depressive disorder and bipolar 
disorder were made according to the DSM-IV (Diagnostic 
and Statistical Manual-IV) criteria (22). The control subjects 
were recruited from hospital staff. The study protocol was 
approved by the Clinical Researches Ethics Committee, and 
the written informed consents were obtained from the 
study participants.
Genotyping
Genomic DNA was extracted from peripheral leukocytes 
from EDTA-anticoagulated blood using the High Pure 
Polymerase Chain Reaction Template Preparation Kit 
(Roche Molecular Biochemicals, Mannheim, Germany) 
according to the manufacturer’s instructions. To identify 
PON1 L55M and Q192R single nucleotide polymorphisms 
(SNPs), genotyping was performed using commercially 
synthesized primers and fluorescently labeled probes 
(Metabion, Martinsried, Germany) and the LightCycler 480 
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II Real-Time Polymerase Chain Reaction System (Roche 
Diagnostics). The genotyping method was based on 
methods developed previously (23) for genotyping both 
PON1 55 and 192 polymorphisms using LightCycler real-
time polymerase chain reaction technology, which relies on 
fluorescence resonance energy transfer. Target fragments of 
the human PON1 gene were amplified with specific primers. 
To detect the PON1 L55M polymorphism, 10 pmol of the 
forward primer 5’-CCTGCAATAATATGAAACAACCTG-3’ 
and the reverse primer 5’-CTAGAACACAGAAAAGTGAAA-
GAAAAC-3’  and 3  pmol  of  the sensor  probe 
5’-CTCTGAAGACATGGAGATACTGCC-fluorescein-3’ and 
the anchor probe 5’-LCRed640-ATGGACTGGCTTTCATTAG
CTCTGTGAGT-3’ were added to genomic DNA. To detect 
the PON1 Q192R polymorphism, we also used 10 pmol of 
the forward primer 5’-ATTGTTGCTGTGGGACCTGAG-3’ 
and the reverse primer 5’-CCTTCTGCCACCACTCGAAC-3’ 
and 3 pmol of the sensor probe
 5’-CCCCTACTTACAATCCTGGGAGAT-fluorescein-3’ 
and the anchor probe 5’-LCRed705-ATTTGGGTTTAG-
CGTGGTCGTATGTTG-3’. Melting curves were transformed 
to melting peaks by plotting the negative derivative of the 
fluorescence signal versus the temperature. The genotypes 
were identified by creating a melting curve with specific 
melting points.
Statistical Analysis
Descriptive analyses were performed to provide 
information on general characteristics of the study 
population. One way ANOVA test was used to compare the 
continuous data among groups. The continuous data were 
presented as the mean±standard deviation. Chi-Square test 
was used to compare the categorical data between/among 
groups. Categorical variables were presented as a count and 
percentage. A p-value <0.05 was considered satistically 
significant. Analyses were performed using SPSS 19 (24). 
RESULTS
The baseline clinical and demographics features of patients 
with major depressive disorder and bipolar disorder are 
shown in Table 1 and Table 2. The mean age of the 
depressed group, bipolar group and controls were 
38.21±12.07, 41.19±12.25 and 37.34±10.21 respectively. No 
significant differences in the mean ages and gender were 
observed between the bipolar patient group and the control 
group. The mean age was not different between depressed 
group and controls but the depressed group was different 
from controls in terms of gender. Namely, the majority of 
the depressed group consisted of females. All the PON1 
Table 1: Baseline clinical and demographics features of the 100 study patients with major depression
Characteristic Depressed patients group
Gender, no. male/female (male %/female %) 13/87 (13.0/87.0)
Age, mean±SD (range) years 38.21±12.07
Table 2: Baseline clinical and demographics features of the 100 study patients with bipolar disorder.
Characteristic Bipolar patients group
Gender, no. male/female (male %/female %) 49/51 (49.0/51.0)
Age, mean±SD (range) years 41.18±12.27
Age of onset, mean±SD (range) years 25.21±9.86
Bipolar disorder subtype, n (%)
Type 1 87 (87)
Type 2 13 (13) 
Rapid cycling, n (%) 17 (17)
Seasonal pattern, n (%) 59 (59 )
Alcohol/drug use, n (%) 10 (10)
Suicidal behavior, n (%) 26 (26)
Psychotic feature, n (%) 55 (55)
Hospitalization, n (%) 69 (69)
Family history of BPD, n (%) 33 (33)
Family history of suicide, n (%) 13 (13)
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gene polymorphisms analyzed were in Hardy–Weinberg 
equilibrium. Allele and genotype frequencies were not 
different between patients with depression and controls in 
with regard to L55M and Q192R polymorphisms of PON1 
(Table 3). Likewise, there was not a significant difference of 
to L55M and Q192R polymorphism between patients with 
bipolar disorder and controls (Table 4). Additionally, there 
were no statistically significant differences between groups 
for presence of PON1 genotypes 
DISCUSSION
The present study examined the L55M and Q192R 
polymorphisms of PON1 gene in patients with depression 
and bipolar disorder. We did not find any associations 
between the L55M and Q192R polymorphisms and major 
depression and bipolar disorder. Also, no association was 
found between the PON1 genotypes and disease variables 
in both patient groups.
 The lack of association between the L55M and Q192R 
polymorphisms and major depressive disorder in the 
present study is in line with Nunes et al’s report (14). 
Although, they did not distinguish depressed and bipolar 
patients and they only looked for the Q192R polymorphisms 
but not for the L55M polymorphisms; but they found no 
associations between patients with mood disorders and 
any of the three PON1 Q192R genotypes. In a similar 
manner, no associations between major depressive 
disorder and the Q192R polymorphism or any other 
polymorphism in the PON1 gene have been found in a 








L/L 40 (41.7) 37 (37.0) 0.56
L/M 42 (43.7) 43 (43.0)
M/M 14 (14.6) 20 (20.0)
Alleles
L 122 (63.5) 117 (58.5) 0.15
M 70 (36.5) 83 (41.5)
PON192Q/R
Q/Q 43 (44.8) 47 (47.0) 0.61
Q/R 39 (40.6) 43 (43.0)
R/R 14 (14.6) 10 (10.0)
Alleles
Q 125 (65.0) 137 (68.5) 0.24
R 67 (35.0) 63 (31.5)








L/L 40 (41.7) 39 (39.0) 0.89
L/M 42 (43.7) 47 (47.0)
M/M 14 (14.6) 14 (14.0)
Alleles
L 122 (63.5) 125 (62.5) 0.41
M 70 (36.5)  75  (37.5)
PON192Q/R
Q/Q 43 (44.8) 44 (44.0) 0.95
Q/R 39 (40.6) 40 (40.0)
R/R 14 (14.6) 16 (16.0)
Alleles
Q 125 (65.0) 128 (64.0) 0.241
R 67 (35.0)  72 (36.0)
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genome-wide association study (15). However, there are 
some contradictory findings. In a study exploring the PON 
Q192R polymorphism in major depressive disorder in 
relation to nicotine dependence, it was demonstrated that 
PON Q192R-smoking interaction might play a role in 
depression (13). A different study including British women 
aged 60–79 years, R allele of PON1 Q192R was found to be 
associated with increased odds of depression (12). Large 
differences between ethnic populations are known in the 
PON1 genotype distribution (25). So, it may be the reason 
for differences among studies. The majority of the subjects 
in the depressed group were female and it was significantly 
different from controls. As it was shown that gender had no 
impact on PON1 polymorphism (26), it was thought that 
the gender difference in the present study did not confound 
the results. The contradictory results are also present for 
PON1 activity. No differences were found in terms of PON1 
activity between patients with depression and controls 
(17,18). A diminished PON1 activity was also reported 
(13,19-20). In addition, long-term AD treatment seems to 
increase the paraoxonase/arylesterase levels in patients 
with depression (20). In the present study, we did not 
measure PON1 activity. As in our study, the vast majority of 
the studies in the literature did not include any measures of 
PON1 activity. 
 We did not find any association between any association 
between the L55M and Q192R polymorphisms and bipolar 
disorder. Ezzaher et al. (2012) demonstrated that carrying 
homozygote or heterozygote mutated alleles of L55M and 
Q192R might cause susceptibility to bipolar I disorder. It 
was indicated that the QQ genotype of Q192R in smokers 
increased the risk of bipolar disorder (13). Our findings are 
consistent with a genome-wide association study reporting 
no associations between bipolar disorder and the Q192R 
polymorphism or any other polymorphism in the PON1 
gene (27). In terms of PON1 activity in bipolar patients; one 
study demonstrated normal activity (13) but the other 
showed decreased PON1 activity (21). The results of the 
present study and the discrepancies between the other 
studies might be associated with the distinct genotypic 
distribution of PON1 across different ethnic populations.
 We also found no associations between clinical 
variables of depression and bipolar disorder and the L55M 
and Q192R polymorphisms of PON1. Diminished serum 
paraoxonase and arylesterase activities and polymorphisms 
of PON1 in humans have been linked to heightened 
systemic oxidative stress (8,28). So, it could be expected 
that the more serious forms of mood disorders might be 
associated with lower levels or lower activity of antioxidant 
properties.
 Polymorphism regarding PON1 has not been studied 
too much in other psychiatric disorders. In a study 
including patients with schizophrenia, their relatives, and 
healthy controls; authors suggested that the subjects 
carrying R allele or RR genotype of Q192R polymorphism 
might be susceptible to schizophrenia and subjects with 
QQ or LL of L55M polymorphism might be protected 
against schizophrenia (29). Another study looked at an 
association between Q192R and L55M polymorphisms of 
PON1 and autism spectrum disorders, but they found no 
associations (30).
 The results of the present study must be interpreted 
within the limitations of the study. First, larger sample size 
of groups would be beneficial and the sample of our 
depressed and bipolar patients may not be representative 
of the whole patient populations. Second, our work is a 
cross-sectional study that does not permit to follow-up of 
biological parameters. The gender differences between 
groups is another limitation. We did not measure PON 
activity but it is the common limitation of such association 
studies. Another limitation of the study is that reports from 
association studies constitute tentative knowledge and 
must be interpreted with caution (31). 
 In conclusion, our findings reported no associations of 
Q192R and L55M polymorphisms of PON1 with major 
depression and bipolar disorder, suggesting that these two 
polymorphisms might not play a role in the pathophysiology 
of mood disorders. There were also no significant 
associations of PON1 polymorphisms with the clinical and 
demographic characteristics of patients. Prospective 
studies with larger sample sizes evaluating the different 
stages of patients examining the connection between PON1 
polymorphisms and treatment outcomes will help us to 
clarify the relationship between PON1 and mood disorders. 
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